Cargando…
Prevalence of autosomal dominant polycystic kidney disease in the European Union
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end-stage renal disease, but estimates of its prevalence vary by >10-fold. The objective of this study was to examine the public health impact of ADPKD in the European Union (EU) by estimating minimum prevalenc...
Autores principales: | Willey, Cynthia J., Blais, Jaime D., Hall, Anthony K., Krasa, Holly B., Makin, Andrew J., Czerwiec, Frank S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837385/ https://www.ncbi.nlm.nih.gov/pubmed/27325254 http://dx.doi.org/10.1093/ndt/gfw240 |
Ejemplares similares
-
Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease
por: Grantham, Jared J., et al.
Publicado: (2017) -
Standardizing total kidney volume measurements for clinical trials of autosomal dominant polycystic kidney disease
por: Edwards, Marie E, et al.
Publicado: (2018) -
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
por: Watkins, Paul B., et al.
Publicado: (2015) -
Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4
por: Devuyst, Olivier, et al.
Publicado: (2017) -
Risk Factors for Pain in Autosomal Dominant Polycystic Kidney Disease: A New Research Trajectory
por: Willey, Cynthia J., et al.
Publicado: (2021)